Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, gives an overview of the current state-of-the art therapies for the treatment of myeloproliferative neoplasms (MPNs) presented at EHA 2021. Dr Pemmaraju highlights three major developments; the large number of Phase III randomized trials, add-on combination strategies, and developments in the treatment of polycythemia vera. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

свернуть